TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03375099

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lethal Means Counseling
Description: Single session motivational interviewing based interaction aimed to increase the safe storage of firearms in an effort to reduce suicide risk.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Lethal Means Counseling
Description: Single session motivational interviewing based interaction aimed to increase the safe storage of firearms in an effort to reduce suicide risk.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health and Stress Reduction
Description: Single session motivational interviewing based interaction aimed to reduce vulnerability to negative outcomes across four domains: sleep, diet, exercise, and stress.
Study: NCT04138238

Intervention type: DEVICE
Intervention: Supraflex Cruz Sirolimus-eluting Stent
Description: Patient implanted with at least one Supraflex Cruz sirolimus-eluting stent as a part of planned clinical care
Study: NCT03498144

Intervention type: DEVICE
Intervention: Anterior segment OCT
Description: lower punctum examination by AS-OCT

Intervention type: DEVICE
Intervention: Anterior segment OCT
Description: lower punctum examination by AS-OCT
Study: NCT02849431

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-based intervention
Description: A version of mindfulness-based cognitive therapy that has been adapted for people with a diagnosis of borderline personality disorder. This comprises eight weekly session, each lasting ninety minutes.
Study: NCT02928874

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EAH (low ED vs. high ED snacks)
Study: NCT02120911

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pertuzumab, trastuzumab
Description: Pertuzumab and trastuzumab will be combined with standard chemoradiation with carboplatin and paclitaxel.
Study: NCT02080650

Intervention type: DEVICE
Group type: OTHER
Intervention: Mesenchymal-marker based ferrofluid (c-MET)

Intervention type: DEVICE
Group type: OTHER
Intervention: Mesenchymal-marker based ferrofluid (c-MET)

Intervention type: DEVICE
Group type: OTHER
Intervention: Mesenchymal-marker based ferrofluid (c-MET)

Intervention type: DEVICE
Group type: OTHER
Intervention: Mesenchymal-marker based ferrofluid (c-MET)

Intervention type: DEVICE
Group type: OTHER
Intervention: Mesenchymal-marker based ferrofluid (c-MET)

Intervention type: DEVICE
Group type: OTHER
Intervention: Mesenchymal-marker based ferrofluid (c-MET)

Intervention type: DEVICE
Group type: OTHER
Intervention: Mesenchymal-marker based ferrofluid (c-MET)

Intervention type: DEVICE
Group type: OTHER
Intervention: Mesenchymal-marker based ferrofluid (c-MET)

Intervention type: DEVICE
Group type: OTHER
Intervention: Epithelial cell adhesion molecule (EpCAM) ferrofluid
Study: NCT00706992

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Aldesleukin
Description: Given subcutaneously

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Aldesleukin
Description: Given subcutaneously

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Aldesleukin
Description: Given subcutaneously

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: autologous anti-MART-1 F5 T-cell receptor gene-engineered peripheral blood lymphocytes
Description: Given intravenously (IV)
Study: NCT03375099

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health and Stress Reduction
Description: Single session motivational interviewing based interaction aimed to reduce vulnerability to negative outcomes across four domains: sleep, diet, exercise, and stress.
Study: NCT00838916

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: albiglutide
Description: albiglutide weekly injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin glargine
Description: insulin glargine
Study: NCT00632541

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: Sorafenib 200mg po daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab 5mg/kg every other week~1 Cycle = 4 weeks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Imaging
Description: Imaging every third cycle
Study: NCT03361878

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin Hydrochloride
Description: Single dose of 500mg oral metformin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin Hydrochloride
Description: Single dose of 500mg oral metformin
Study: NCT02136784

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: morphine sulfate
Description: Participants will receive randomly assigned order of study drug (opioid) and then have 7 days of testing with test days at least 3 days apart. Pain testing will utilize cold pressor test, in which the participant submerges his arm and hand in a bath of ice cold water to determine pain threshold and tolerance.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: hydrocodone
Description: Participants will receive randomly assigned order of study drug (opioid) and then have 7 days of testing with test days at least 3 days apart. Pain testing will utilize cold pressor test, in which the participant submerges his arm and hand in a bath of ice cold water to determine pain threshold and tolerance.
Study: NCT01922284

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DNA
Description: 8mg DNA: one plasmid encoding a gag-pol-nef polypeptide derived from the 96ZM651-8 clone and one plasmid encoding gp140 env derived from clade C 97CN54

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: DNA
Description: 8mg DNA: one plasmid encoding a gag-pol-nef polypeptide derived from the 96ZM651-8 clone and one plasmid encoding gp140 env derived from clade C 97CN54

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA-C
Description: 1.108 TCID50 MVA-C (nominal titre) expressing the gag-pol-nef and gp120 env proteins derived from clade C 97CN54

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: MVA-C
Description: 1.108 TCID50 MVA-C (nominal titre) expressing the gag-pol-nef and gp120 env proteins derived from clade C 97CN54

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CN54rgp140
Description: 100ug CN54rgp140, a trimeric recombinant envelope protein derived from clade C 97CN54

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: CN54rgp140
Description: 100ug CN54rgp140, a trimeric recombinant envelope protein derived from clade C 97CN54

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GLA-AF
Description: 5ug GLA-AF, an aqueous glucopyranosyl lipid A adjuvant

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: GLA-AF
Description: 5ug GLA-AF, an aqueous glucopyranosyl lipid A adjuvant
Study: NCT04199208

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Prehabilitation and Immunonutrition
Description: See study synopsis

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care Arm
Description: Standard care as per the daily routines of the Hospital at which the study takes place
Study: NCT00617318

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Pomegranate
Description: All subjects were randomized and assigned to a 16-week treatment with either POM concentrate or placebo. The placebo matched the taste, smell, and appearance of the POM concentrate. Supplies were shipped to the investigation site in equal proportions marked as A and B, and site personnel did not know the code. The treatment products (POM concentrate or placebo) were supplied as 2-oz packages, each containing a single day's consumption, and were dispensed as packages of 33 units (a 4-week plus 5-day supply). The subjects were to consume one 2 oz. package daily for a period of 16 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: All subjects were randomized and assigned to a 16-week treatment with either POM concentrate or placebo. The placebo matched the taste, smell, and appearance of the POM concentrate. Supplies were shipped to the investigation site in equal proportions marked as A and B, and site personnel did not know the code. The treatment products (POM concentrate or placebo) were supplied as 2-oz packages, each containing a single day's consumption, and were dispensed as packages of 33 units (a 4-week plus 5-day supply). The subjects were to consume one 2 oz. package daily for a period of 16 weeks.
Study: NCT02780765

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: heated humidifier
Description: 30 patients requiring overnight intubation but breathing spontaneously without ventilatory support will be supplied humidified oxygen using Heated Humidifier(HH)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: mist humidifier
Description: 30 patients requiring overnight intubation but breathing spontaneously without ventilatory support will be supplied humidified oxygen using mist humidifier
Study: NCT00171314

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zoledronic acid
Description: Zoledronic acid 4 mg Intravenous (IV)15 minute infusion every 6 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zoledronic acid
Description: Zoledronic acid 4 mg Intravenous (IV)15 minute infusion every 6 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: Letrozole tablets 2.5 mg/day/taken orally for 5 years.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: Letrozole tablets 2.5 mg/day/taken orally for 5 years.
Study: NCT00650091

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: N-acetylcysteine (NAC)
Description: Participants will receive 600 mg of NAC three times a day.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive placebo each day.
Study: NCT03810209

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Magnesium Sulphate
Description: adding magnesium sulphate to local anaesthetic in SAP Block

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: adding normal saline to local anaesthetic in SAP block
Study: NCT02136784

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: hydromorphone HCI
Description: Participants will receive randomly assigned order of study drug (opioid) and then have 7 days of testing with test days at least 3 days apart. Pain testing will utilize cold pressor test, in which the participant submerges his arm and hand in a bath of ice cold water to determine pain threshold and tolerance.
Study: NCT02909569

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCB039110
Description: All subjects will receive 400 mg PO QD for 12 weeks. If no clinical response after four weeks, dose will be increased to 600 mg PO QD. Total duration of subject participation will be six study visit over 20 weeks.
Study: NCT01010711

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Migra 3
Description: powder containing coenzyme q10, blueberries, black current, vitamins, magnesium,trace elements
Study: NCT02136784

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: oxycodone
Description: Participants will receive randomly assigned order of study drug (opioid) and then have 7 days of testing with test days at least 3 days apart. Pain testing will utilize cold pressor test, in which the participant submerges his arm and hand in a bath of ice cold water to determine pain threshold and tolerance.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: buprenorphine
Description: Participants will receive randomly assigned order of study drug (opioid) and then have 7 days of testing with test days at least 3 days apart. Pain testing will utilize cold pressor test, in which the participant submerges his arm and hand in a bath of ice cold water to determine pain threshold and tolerance.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oral tablet placebo
Description: Participants will receive randomly assigned order of study drug (opioid) and then have 7 days of testing with test days at least 3 days apart. Pain testing will utilize cold pressor test, in which the participant submerges his arm and hand in a bath of ice cold water to determine pain threshold and tolerance.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oral tablet placebo
Description: Participants will receive randomly assigned order of study drug (opioid) and then have 7 days of testing with test days at least 3 days apart. Pain testing will utilize cold pressor test, in which the participant submerges his arm and hand in a bath of ice cold water to determine pain threshold and tolerance.
Study: NCT01205451

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A
Description: Botulinum toxin type A
Study: NCT03739476

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quetiapine 25 milligrams capsule
Description: Compare the incidence of postoperative delirium.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Compare the incidence of postoperative delirium.
Study: NCT03347604

Intervention type: DIAGNOSTIC_TEST
Intervention: Supine spirometry, MIPs and MEPs
Description: We are going to test spirometry while in supine position , and also test respiratory muscles by measuring the maximum inspiratory and maximum expiratory efforts made by patients.
Study: NCT01032993

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Coenzyme Q10
Description: 300 mg of CoQ10 (three 100 mg chewable tablets) 2 times daily for 4 weeks

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (three chewable tablets) 2 times daily for 4 weeks
Study: NCT00945802

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FST-201 (dexamethasone 0.1%) Otic Suspension
Description: Instill four drops two times a day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ciprofloxacin 0.3%, dexamethasone 0.1%
Description: Instill four drops two times a day
Study: NCT00994656

Intervention type: DEVICE
Intervention: Masimo multi-wavelength pulse co-oximeter
Description: Subjects will have a finger probe that will measure the pleth variability index. They will also have an arterial line (as standard of care) from which arterial pulse tracings will be obtained.
Study: NCT01345097

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Total Hip Arthroplasty
Description: Total Hip Arthroplasty

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Total Hip Arthroplasty
Description: Total Hip Arthroplasty
Study: NCT01451034

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: WHYX cancer group
Description: WHYX cancer diagnosed by pathologic report

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: WHYX cancer group
Description: WHYX cancer diagnosed by pathologic report
Study: NCT04915924

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HeartMate 3™ left ventricular assist system (HM3 LVAS)
Description: Advanced heart failure patients will be implanted with the HM3 LVAS
Study: NCT01498081

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD2115
Description: AZD2115 administered via inhalation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD2115
Description: AZD2115 administered via inhalation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD2115
Description: AZD2115 administered via inhalation

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered via inhalation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Indacaterol
Description: Indacaterol administered via inhalation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Indacaterol + Tiotropium
Description: Indacaterol + Tiotropium administered inhalation
Study: NCT01070524

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHF 5188 pMDI
Description: CHF 5188: fixed combination budesonide/carmoterol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Budesonide extrafine pMDI
Description: Budesonide extrafine pMDI

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Seretide(r) Evohaler(r)
Description: Seretide(r) Evohaler(r): fixed combination fluticasone/salmeterol
Study: NCT03046940

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient-centered style of communication
Description: Different doctor-patient communication

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Doctor-centered style of communication
Description: Different doctor-patient communication
Study: NCT02136784

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oral tablet placebo
Description: Participants will receive randomly assigned order of study drug (opioid) and then have 7 days of testing with test days at least 3 days apart. Pain testing will utilize cold pressor test, in which the participant submerges his arm and hand in a bath of ice cold water to determine pain threshold and tolerance.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oral tablet placebo
Description: Participants will receive randomly assigned order of study drug (opioid) and then have 7 days of testing with test days at least 3 days apart. Pain testing will utilize cold pressor test, in which the participant submerges his arm and hand in a bath of ice cold water to determine pain threshold and tolerance.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sublingual tablet placebo
Description: Participants will receive randomly assigned order of study drug (opioid) and then have 7 days of testing with test days at least 3 days apart. Pain testing will utilize cold pressor test, in which the participant submerges his arm and hand in a bath of ice cold water to determine pain threshold and tolerance.
Study: NCT03973957

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Indwelling pleural catheter placement
Description: Indwelling pleural catheter placement by interventional pulmonologist

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Indwelling pleural catheter placement
Description: Indwelling pleural catheter placement by interventional pulmonologist

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl Citrate
Description: Administration of intravenous fentanyl prior to talc slurry instillation in order to avoid pain associated with talc slurry application

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl Citrate
Description: Administration of intravenous fentanyl prior to talc slurry instillation in order to avoid pain associated with talc slurry application

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Talc Slurry
Description: Administration of 5 grams of medical grade sterile talc mixed in 50 milliliters of normal saline solution via indwelling pleural catheter for purposes of talc slurry pleurodesis

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Talc Slurry
Description: Administration of 5 grams of medical grade sterile talc mixed in 50 milliliters of normal saline solution via indwelling pleural catheter for purposes of talc slurry pleurodesis

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Drainage collection bag
Description: Attachment of one-way Heimlich valve with drainage collection bag circuit to indwelling pleural catheter after talc slurry application for purposes of drainage and pleurodesis in the outpatient setting rather than the inpatient setting.
Study: NCT00706992

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: autologous anti-MART-1 F5 T-cell receptor gene-engineered peripheral blood lymphocytes
Description: Given intravenously (IV)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: autologous anti-MART-1 F5 T-cell receptor gene-engineered peripheral blood lymphocytes
Description: Given intravenously (IV)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: autologous anti-MART-1 F5 T-cell receptor gene-engineered peripheral blood lymphocytes
Description: Given intravenously (IV)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: autologous anti-MART-1 F5 T-cell receptor gene-engineered peripheral blood lymphocytes
Description: Given intravenously (IV)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: autologous anti-MART-1 F5 T-cell receptor gene-engineered peripheral blood lymphocytes
Description: Given intravenously (IV)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: autologous anti-MART-1 F5 T-cell receptor gene-engineered peripheral blood lymphocytes
Description: Given intravenously (IV)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: incomplete Freund's adjuvant
Description: Given subcutaneously

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: incomplete Freund's adjuvant
Description: Given subcutaneously
Study: NCT01289951

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Raltegravir 400 mg/12hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raltegravir 400 mg/12hours
Study: NCT03560921

Intervention type: DIAGNOSTIC_TEST
Intervention: urinary NGAL
Description: measurement urinary NGAL using the ARCHITECT technique

Intervention type: DIAGNOSTIC_TEST
Intervention: urinary NGAL
Description: measurement urinary NGAL using the ARCHITECT technique
Study: NCT02713815

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: repetitive transcranial magnetic stimulation (rTMS)
Description: Stimulate the dorsomedial prefrontal cortex for 4 weeks by Theta-burst stimulation (TBS), once a day

Intervention type: RADIATION
Group type: SHAM_COMPARATOR
Intervention: sham repetitive transcranial magnetic stimulation (rTMS)
Description: Stimulate the dorsomedial prefrontal cortex for 4 weeks by sham Theta-burst stimulation (TBS), once a day
Study: NCT00678626

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-751,871
Description: Docetaxel administered every 3 weeks. CP-751,871 administered every 3 weeks. CP-751,871 administration (20 mg/kg IV) will continue after the docetaxel is stopped.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Docetaxel only is administered every 3 weeks. After progression, administration with CP-751, 871 (20 mg/kg IV) is permitted.
Study: NCT00903552

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza VLP Vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza VLP Vaccine

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: phosphate-buffered saline (PBS)
Study: NCT03046719

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine 0,5%
Description: Bupivacaine 0,5% was given on the subconjunctiva, in between stitches by the surgeon after finishing the last stitches

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NaCl 0,9%
Description: NaCl 0,9% was given on the subconjunctiva, in between stitches by the surgeon after finishing the last stitches